Harlan S. Robins, serving as the Chief Scientific Officer for Adaptive Biotechnologies Corp. (NASDAQ: ADPT), has completed a substantial liquidation of company equity. On July 2, 2026, Robins sold a total of 386,240 shares of the company's common stock. The aggregate value of these transactions reached approximately $8.5 million. These sales were executed under the framework of a pre-arranged Rule 10b5-1 trading plan, which Robins adopted on March 13, 2026. The use of this automated plan indicates the transactions were scheduled in advance, independent of immediate market conditions or personal trading decisions at the time of execution.
The divestment was carried out through two distinct transactions. In the initial phase, Robins sold 239,351 shares at a weighted-average price of $21.74 per share. The execution prices for this portion of the sale ranged from $21.15 to $22.145 per share. The subsequent transaction involved the sale of 146,889 shares at a weighted-average price of $22.45 per share. Individual sale prices in this second tranche ranged from $22.15 to $22.75 per share. These sales occurred at a time when the stock price was trading near its 52-week high of $22.80. This valuation point follows a significant 77% gain in the stock price over the past year.
Following the completion of these transactions, Robins retains direct ownership of 1,019,658 shares of Adaptive Biotechnologies common stock. The sale activity occurs against a backdrop of strong financial performance for the company. Adaptive Biotechnologies recently reported financial results for the first quarter of 2026 that surpassed market expectations. Revenue for the quarter reached $70.9 million, a figure that significantly exceeded the forecast of $60.89 million. This represents a 16.4% increase in revenue, which was largely attributed to the expansion of its Minimal Residual Disease (MRD) business.
In addition to financial results, the company has outlined strategic structural changes. Adaptive Biotechnologies announced plans to separate its MRD and Immune Medicine units. The company aims to identify the preferred path for this separation by the end of 2026. Furthermore, the company revealed an upsized offering of $300 million in convertible senior notes. This offering was initially planned at $250 million but was increased. The notes will be offered in a private placement, with an option for initial purchasers to acquire an additional $37.5 million in notes. BTIG has reiterated its Buy rating on the company's stock, maintaining a price target of $22.00 following these announcements.
Market analysis from InvestingPro suggests that ADPT currently appears overvalued relative to its Fair Value estimate. This assessment places the stock among those on the Most Overvalued list based on current valuation metrics. The company's stock price was recorded at $20.82, reflecting a decrease of $0.680 or -3.16% from the previous close. After-hours trading showed a minor decline of $0.010 or -0.05%, with the price at $20.81.